Liraglutide for the treatment of type 2 diabetes.

Health technology assessment (Winchester, England)

Volumn 15 Suppl 1, Issue , 2011, Pages 77-86

  Shyangdan, D ^a   Cummins, E ^b   Royle, P ^b   Waugh, N ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; LIRAGLUTIDE; METFORMIN;

COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION;

CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; META-ANALYSIS AS TOPIC; METFORMIN; MULTICENTER STUDIES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT LOSS;

MLCS; MLOWN;

EID: 84886943000     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta15suppl1/09     Document Type: Review

References (0)